Fundraising Fox
/Companies
Sign in

Converge Bio

Claymont, US · Founded 2024 · Delaware corporation · 53 employees on LinkedIn · 4 known investors

Find your way into Converge Bio

Sign up to see every warm intro you have to Converge Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Converge Bio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Converge Bio develops generative AI models trained on DNA, RNA, and protein sequences to support drug discovery and development for biotech and pharmaceutical companies. The company provides AI solutions for target discovery, antibody design, protein manufacturing optimization, and biomarker discovery.

AI & Machine LearningBiotechDeep Tech

Founders & leadership

Converge Bio was founded in 2024 by Dov Gertz.

DGDov Gertz
Dov GertzCEO & Co-Founder
OKOded Kalev
Oded KalevCTO & Co Founder
IWIddo Weiner
Iddo WeinerCSO & Co-Founder
DG
Dov Gertz Oded KalevFounder
IW
Iddo WienerFounder

Board

STShahar Tzafrir
Shahar TzafrirBoard directorManaging Partner at TLV Partners
AHAndrew Hedin
Andrew HedinBoard directorPartner at Bessemer Venture Partners

Investors · 4

TLV Partnerslisted by TLV PartnersTel Aviv · $2M – $8M

How we know: TLV Partners's portfolio page · a partner's Signal profile · funding news · techcrunch.com · the VCSheet dataset · Not right? Tell us

SARAS CAPITALreportedCanterbury

How we know: techcrunch.com · Not right? Tell us

Vintage Investment PartnersreportedHerzliya

How we know: techcrunch.com · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$25M disclosed across 1 round · 2025

▶$25MraisedApr 2026 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Shahar TzafrirDirector
  • Dov GertzExecutive Officer, Director
  • Oded KalevExecutive Officer, Director
  • Andrew HedinDirector
  • Iddo WeinerExecutive Officer
Offering amount
$25M
Amount sold
$25M
First sale
Sep 2025
Incorporated
Corporation, Delaware, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 8

BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Transition BioTransition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease. The company is a platform-based biotherapeutics developer founded on academic research from the University of Cambridge.
Generate BiomedicinesGenerate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering. The company creates new drugs on demand across diverse biologic modalities for immunology, oncology, infectious disease, and vaccines.
Engage BioEngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.
Formation BioFormation Bio develops drugs through partnerships with health systems, academic medical centers, and research sites, focusing on clinical trials in dermatology, rheumatology, and cardiometabolic diseases. The company provides trial management infrastructure, monitoring, technology, and enrollment support to accelerate drug development.
Maven BioMaven Bio provides software for biotech investment firms to accelerate due diligence and thesis development, automating screening, competitive analysis, and clinical data review to compress research timelines from days to hours.
Form BioForm Bio develops AI-driven software and bioinformatics tools for genetic medicine and genome engineering, enabling faster and safer design of gene therapies, protein engineering, and manufacturing optimization.
AskBioAskBio is a gene therapy company developing adeno-associated virus (AAV)-based genetic medicines for rare and other diseases, with clinical programs such as AB-1009 for late-onset Pompe disease. It operates as a wholly owned, independent subsidiary of Bayer AG.

Companies working in the same space as Converge Bio.

In the news

Converge Bio Raises $25M in Series A Fundingfinsmes.com · Jan 2026Converge Bio raises $25M to bring generative AI drug discovery to every biotech and pharmaceutical companyprnewswire.com · Jan 2026Converge Bio raises $25M, backed by Bessemer and execs from Meta, OpenAI, Wiz | TechCrunchtechcrunch.com · Jan 2026

Frequently asked questions

What does Converge Bio do?
Converge Bio develops generative AI models trained on DNA, RNA, and protein sequences to support drug discovery and development for biotech and pharmaceutical companies. The company provides AI solutions for target discovery, antibody design, protein manufacturing optimization, and biomarker discovery.
Who founded Converge Bio?
Converge Bio was founded by Dov Gertz in 2024.
Who are Converge Bio's investors?
Converge Bio's investors include Bessemer Venture Partners, TLV Partners, SARAS CAPITAL, Vintage Investment Partners.
How much funding has Converge Bio raised?
Converge Bio has disclosed $25M raised across 1 round.
Where is Converge Bio headquartered?
Converge Bio is headquartered in Claymont, US.